David Kirske - 14 Jun 2022 Form 4 Insider Report for CTI BIOPHARMA CORP

Role
EVP, Chief Financial Officer
Signature
David Kirske
Issuer symbol
N/A
Transactions as of
14 Jun 2022
Net transactions value
-$45,511
Form type
4
Filing time
16 Jun 2022, 16:19:11 UTC
Previous filing
11 Mar 2022
Next filing
17 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC common stock Options Exercise $9,489 +10,000 +135% $0.9489 17,397 14 Jun 2022 Direct
transaction CTIC common stock Sale $55,000 -10,000 -57% $5.50 7,397 14 Jun 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -10,000 -2% $0.000000 490,000 14 Jun 2022 Common Stock 10,000 $0.9489 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person.
F2 One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.